City of Hope Medical Center clinical trials
City of Hope Medical Center is the lead sponsor of 17 current clinical trials in our Japan, Egypt, Spain, China, Italy, Canada, Mexico, South Korea and Israel registers. 14 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Avastin, BP102 and Bevacizumab. The most-studied condition is Colorectal Cancer.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by City of Hope Medical Center
17 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT06342414 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma
|
Observational | Recruiting | 2024-03 | Japan |
|
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
NCT06490003 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, DNA Methylation
Drug: Cisplatin |
Observational | Recruiting | 2004-06 | Japan |
|
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
NCT06476067 · ClinicalTrials.gov ↗ · Esophageal Cancer, Recurrence, DNA Methylation
|
Observational | Recruiting | 2006-01 | Japan |
|
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935 · ClinicalTrials.gov ↗ · Malignant Neoplasm
|
Observational | Recruiting | 1997-04 | Mexico |
|
Pancreatic Cancer Detection Consortium
NCT06388967 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma
|
Observational | Recruiting | 2023-03 | Japan, South Korea |
|
Early Onset Colorectal Cancer Detection
NCT06342401 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma
|
Observational | Recruiting | 2023-04 | Spain, Italy, Japan |
|
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
NCT07225738 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Observational | Recruiting | 2026-01 | Egypt |
|
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
NCT07288034 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
|
Phase 2 | Recruiting | 2026-05 | Egypt |
|
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
NCT07271355 · ClinicalTrials.gov ↗ · Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
|
Phase 3 | Recruiting | 2027-01 | Egypt |
|
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT06342440 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp
|
Observational | Recruiting | 2020-03 | China, Spain, Italy, Japan |
|
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
NCT07595874 · ClinicalTrials.gov ↗ · Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma
Drugs: Balstilimab, Botensilimab |
Phase 2 | Recruiting | 2026-07 | Egypt |
|
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT07125729 · ClinicalTrials.gov ↗ · Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
|
Not applicable | Recruiting | 2025-08 | Egypt |
|
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
NCT06490159 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy-induced Peripheral Neuropathy, Paclitaxel
Drugs: Paclitaxel, Ramucirumab |
Observational | Recruiting | 2018-10 | Japan |
|
Stage II/III Colorectal Cancer Recurrence
NCT06314958 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II
|
Observational | Recruiting | 2023-03 | China, Spain |
|
CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial
NCT07842965 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
Drugs: Floxuridine, Leronlimab |
Phase 1 | Not yet open | 2027-05 | Egypt |
|
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
NCT03712202 · ClinicalTrials.gov ↗ · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma
|
Phase 2 | Active, closed | 2018-11 | Israel |
|
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500 · ClinicalTrials.gov ↗ · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
|
Phase 2 | Active, closed | 2017-12 | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in City of Hope Medical Center trials
39 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in City of Hope Medical Center trials
50 conditionsBy trial register
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Colorectal Cancer
Sponsors with the most current trials registered for this condition.
Questions about City of Hope Medical Center trials
How many clinical trials does City of Hope Medical Center sponsor?
City of Hope Medical Center is the lead sponsor of 17 current trials on ClinicalTrials.gov in our Japan, Egypt, Spain, China, Italy, Canada, Mexico, South Korea and Israel registers, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.
Are City of Hope Medical Center trials recruiting?
Yes. 14 of its 17 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is City of Hope Medical Center testing?
Its current trials name 39 drugs and biologicals as interventions. The most frequent are Avastin (2), BP102 (2), Bevacizumab (2), Bevacizumab-awwb (2) and Brentuximab Vedotin (2). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.